Refine Search

All active links listed wil take you to that organisations's website and they are responsible for keeping information up-to-date.

Displaying 31-40 of 270 result(s)

 
 

Myelodysplastic Syndrome (MDS) - RAEB Refractory Anaemia with Excess Blasts (fact sheet)

This fact sheet provides information about Refractory Anaemia with Excess Blasts (RAEB), especially how it is treated. RAEB 1 and 2 constitutes about 40% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Lymphoma - Follicular (fact sheet)

Follicular lymphoma is the most common subtype of low grade (indolent) lymphoma, making up 20-30% of all non-Hodgkin lymphomas.This Fact sheet provides information about symptoms, people whom could be affected, causes and treatments of Follicular Lymphoma.

Cancer type: Leukaemia, Lymphoma
Written for: Men, Women
Focusing on: Disease stages, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2012

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) – RCMD Refractory Cytopenia with Multilineage Dysplasia (fact sheet)

This fact sheet provides information about whom RCMD will affect and how it is treated. RCMD constitutes about 30% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) – RCUD Refractory Cytopenia with Unilineage Dysplasia (fact sheet)

This Fact sheet provides information on Refractory Cytopenia with Unilineage Dysplasia (RCUD) which constitutes about 10-20% of all cases of Myelodysplastic Syndrome (MDS). It includes what MDS and RCUD are, treatment and side effects. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) - RARS - Refractory Anaemia with Ring Sideroblasts (fact sheet)

This fact sheet includes what is Myelodysplastic syndrome (MDS) and Refractory Anaemia with Ring Sideroblasts (RARS), the risk RARS in transforming to acute myeloid leukaemia (AML),who will be affected and its treatment. RARS constitutes about 3-11% of all MDS cases. For many people, MDS can remain stable for many years causing few symptoms. For others, it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Disease stages, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

About Bortezomib (Myeloma) (fact sheet)

This fact sheet provides information about Bortezomib (Velcade®). Bortezomib is the first in a new class of anti-cancer drugs. This fact sheet includes how Bortezomib works and how it is administrated.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Lenalidomide (Myeloma) (fact sheet)

This fact sheet provides information on what Lenalidomide is, its dosage and side effects. Lenalidomide is an immunomodulatory drug (IMiD). Lenalidomide, which is related to thalidomide (Thalomid®) was approved in Australia in 2007 as a treatment for multiple myeloma which has progressed on another therapy. Lenalidomide is often combined with dexamethasone in the treatment of multiple myeloma.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Lymphoma - What is it? (fact sheet)

More than 5000 Australians are expected to be diagnosed with a form of lymphoma in 2012 - equivalent to 13 people every day.This fact sheet provides information on what lymphoma is, who will be affected and its treatment.

Cancer type: Leukaemia, Lymphoma
Written for: Men, Women
Focusing on: Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2011

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Myelodysplastic Syndrome (MDS) - with Deletion 5q Abnormality (fact sheet)

This fact sheet provides information about the potential cause of Myelodysplastic Syndrome (MDS), its treatment and side effect. Deletion 5q is a rare form of MDS. For many people, MDS can remain stable for many years causing few symptoms. For others it may progress rapidly into a different subtype of MDS or transform into an acute leukaemia.

Cancer type: Leukaemia, Myeloma
Written for: Men, Women
Focusing on: Check ups, Communicating with health and medical staff, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2013

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Chronic Lymphocytic Leukaemia (CLL) & Small Lymphocytic Lymphoma (SLL) (fact sheet)

This fact sheet provides information on symptoms for Chronic Lymphocytic Leukaemia (CLL) & Small Lymphocytic Lymphoma (SLL), who does SLL/CLL affect and their treatments.

Cancer type: Leukaemia, Lymphoma
Written for: Men, Women
Focusing on: Communicating with GPs, Managing symptoms and side effects, Treatment options
Targeting: Partners, family and friends of people with cancer, People with Cancer

Year the publication was first published or reviewed:2012

Last updated on this website:
16-04-2015

By: Leukaemia Foundation
 

Do you know of other resourceful websites? Why not let us know

Report bad content

Please enter the letters as they are shown in the image above. Letters are not case-sensitive.